[go: up one dir, main page]

WO2009127974A3 - 심혈관계 질환 치료용 약제학적 제제 - Google Patents

심혈관계 질환 치료용 약제학적 제제 Download PDF

Info

Publication number
WO2009127974A3
WO2009127974A3 PCT/IB2009/006277 IB2009006277W WO2009127974A3 WO 2009127974 A3 WO2009127974 A3 WO 2009127974A3 IB 2009006277 W IB2009006277 W IB 2009006277W WO 2009127974 A3 WO2009127974 A3 WO 2009127974A3
Authority
WO
WIPO (PCT)
Prior art keywords
drugs
agent
release portion
formulation
hypolipidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2009/006277
Other languages
English (en)
French (fr)
Other versions
WO2009127974A2 (ko
Inventor
김성욱
전성수
구자성
김진욱
박선우
장석영
이상주
조영관
이준영
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanall Pharmaceutical Co Ltd
Original Assignee
Hanall Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Pharmaceutical Co Ltd filed Critical Hanall Pharmaceutical Co Ltd
Publication of WO2009127974A2 publication Critical patent/WO2009127974A2/ko
Publication of WO2009127974A3 publication Critical patent/WO2009127974A3/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 약리학적 활성성분으로 스타틴계 지질저하제, 그의 이성질체, 또는 그의 약학적으로 허용가능한 염을 포함하는 선방출성 구획, 및 약리학적 활성성분으로 디히드로피리딘계 칼슘 채널 차단제, 그의 이성질체, 또는 그의 약제학적으로 허용가능한 염을 포함하는 지연방출성 구획을 포함하는 약제학적 제제를 제공한다. 본 발명에 의한 스타틴계 지질저하제를 함유하는 선방출성 구획, 및 디히드로피리딘계 칼슘 채널 차단제를 함유하는 지연방출성 구획을 포함하는 약제학적 제제는 대사 증후군 및 인슐린 저항성 환자 및 당뇨병 혹은 당뇨병 전증으로 의심되는 환자들의 심혈관 질환, 심폐 질환, 폐질환 또는 신장 질환의 예방 또는 치료에서 약리학적, 임상학적, 과학적 및 경제적으로 각각의 약물의 단일 제제 및 단순 복합 제제보다 매우 유용하다. 본 발명에 의한 제제는 스타틴계 지질저하제와 디히드로피리딘계 칼슘채널 차단제의 용출속도를 달리 구성하여 약물 상호간의 길항 작용 및 부작용을 방지하고, 2종의 약물을 단회 투여함으로써 환자의 복용을 용이하게 하는 효과를 나타낸다.
PCT/IB2009/006277 2008-02-22 2009-02-23 심혈관계 질환 치료용 약제학적 제제 Ceased WO2009127974A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20080016516 2008-02-22
KR10-2008-0016516 2008-02-22

Publications (2)

Publication Number Publication Date
WO2009127974A2 WO2009127974A2 (ko) 2009-10-22
WO2009127974A3 true WO2009127974A3 (ko) 2010-03-25

Family

ID=41199515

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2009/000331 Ceased WO2009127922A2 (ko) 2008-02-22 2009-02-23 심혈관계 질환 치료용 약제학적 제제
PCT/IB2009/006277 Ceased WO2009127974A2 (ko) 2008-02-22 2009-02-23 심혈관계 질환 치료용 약제학적 제제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/000331 Ceased WO2009127922A2 (ko) 2008-02-22 2009-02-23 심혈관계 질환 치료용 약제학적 제제

Country Status (2)

Country Link
KR (5) KR101207618B1 (ko)
WO (2) WO2009127922A2 (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101143559B1 (ko) 2009-09-25 2012-05-24 기아자동차주식회사 오일유로 통합형 엔진브레이크 장치
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
KR101466617B1 (ko) * 2011-11-17 2014-11-28 한미약품 주식회사 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
JP2015503555A (ja) * 2012-05-11 2015-02-02 ハナル・バイオファーマ・カンパニー・リミテッド ボセンタン制御放出性経口製剤
KR20140001357A (ko) * 2012-06-26 2014-01-07 현대약품 주식회사 아세브로필린을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물
CN104161960A (zh) * 2014-09-02 2014-11-26 济南超舜中药科技有限公司 一种治疗肺心病的醋饮及其制备方法
WO2016138072A1 (en) * 2015-02-27 2016-09-01 Ecolab Usa Inc. Compositions for enhanced oil recovery
PL3320903T3 (pl) * 2015-07-08 2021-12-06 Hk Inno.N Corporation Kompozycja farmaceutyczna zawierająca amlodypinę, walsartan i rosuwastatynę
US10413543B2 (en) * 2015-09-01 2019-09-17 Sun Pharma Advanced Research Company Ltd. Stable multiparticulate pharmaceutical composition of rosuvastatin
WO2017196938A1 (en) 2016-05-13 2017-11-16 Ecolab USA, Inc. Corrosion inhibitor compositions and methods of using same
WO2018005341A1 (en) 2016-06-28 2018-01-04 Ecolab USA, Inc. Composition, method and use for enhanced oil recovery
KR20190043076A (ko) * 2017-10-17 2019-04-25 한미약품 주식회사 암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
KR102265977B1 (ko) * 2018-07-16 2021-06-16 주식회사 코피텍 방습성이 개선된 필름 코팅용 조성물 및 이를 코팅한 정제
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
AU2022253899A1 (en) 2021-04-07 2023-10-26 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
KR102730602B1 (ko) * 2021-06-24 2024-11-18 주식회사 종근당 칸데사르탄, 암로디핀 및 아토르바스타틴을 포함하는 약제학적 복합제제
KR102608853B1 (ko) * 2021-11-15 2023-12-01 재단법인 아산사회복지재단 대사질환 개선용 생체발광 캡슐
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022385A (ko) * 1997-08-29 2001-03-15 실버스타인 아써 에이. 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물
KR20050016452A (ko) * 2002-05-29 2005-02-21 노파르티스 아게 Ｄｐｐ ⅳ 억제제와 심혈관계 화합물의 조합물
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004517919A (ja) * 2001-01-26 2004-06-17 シェーリング　コーポレイション 血管状態の処置のための心臓血管薬剤とステロール吸収インヒビターとの組み合わせ
WO2008023869A1 (en) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Combined pharmeceutical formulation with controlled-release comprising dihydropyridine calcium channel blockers and hmg-coa reductase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010022385A (ko) * 1997-08-29 2001-03-15 실버스타인 아써 에이. 암로디핀 및 스타틴 화합물을 포함하는 복합 조성물
KR20050016452A (ko) * 2002-05-29 2005-02-21 노파르티스 아게 Ｄｐｐ ⅳ 억제제와 심혈관계 화합물의 조합물
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR20070078625A (ko) * 2006-01-27 2007-08-01 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법

Also Published As

Publication number Publication date
KR20090091077A (ko) 2009-08-26
WO2009127922A3 (ko) 2009-12-10
KR101207618B1 (ko) 2012-12-04
KR20090091085A (ko) 2009-08-26
KR20090091083A (ko) 2009-08-26
KR20090091080A (ko) 2009-08-26
WO2009127974A2 (ko) 2009-10-22
KR20090091084A (ko) 2009-08-26
WO2009127922A2 (ko) 2009-10-22
KR101181172B1 (ko) 2012-09-18

Similar Documents

Publication Publication Date Title
WO2009127974A3 (ko) 심혈관계 질환 치료용 약제학적 제제
JP2019517542A5 (ko)
WO2008027557A3 (en) Topiramate compositions and methods of enhancing its bioavailability
JP2013505282A5 (ko)
IL192104A (en) Formulation suitable for subcutaneous administration containing molecules of ctla4ig, sugar and liquid liquid pharmacist acceptable and its use in drug preparation
JP2009541348A5 (ko)
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MX2013011174A (es) Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2.
JP2016539921A5 (ko)
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2010020856A3 (en) Rate modulated delivery of drugs from a composite delivery system
JP2013541583A5 (ko)
WO2011159100A3 (ko) 항암 활성을 나타내는 약제학적 조성물
JP2005508963A5 (ko)
WO2017182873A3 (en) Peptide-oligourea foldamer compounds and methods of their use
CN104884051A (zh) 包含吉格列汀和二甲双胍的组合药物及其制备方法
WO2007145863A3 (en) Sustained release formulation of naltrexone
FI3352735T3 (fi) Pitkitetysti vapauttavia olantsapiiniformulaatioita
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2007144081A3 (de) Raucherentwöhnungs-kombinationswafer
WO2010044581A3 (ko) N1-벤조[1,3]다이옥솔-5-일메틸-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물
Kim et al. A randomized, double-blind, multicenter, phase III study to evaluate the efficacy and safety of fimasartan/amlodipine combined therapy versus fimasartan monotherapy in patients with essential hypertension unresponsive to fimasartan monotherapy
JP2016510040A5 (ko)
WO2012163088A3 (zh) 肾病和心脏病的治疗药物及其用途
WO2009125944A3 (ko) 비디히드로피리딘계 칼슘 채널 차단제 및 안지오텐신-2 수용체 차단제를 포함하는 약제학적 제제

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09731891

Country of ref document: EP

Kind code of ref document: A2